Intermediate and high risk localized, completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor: a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versus no furthrer therapy complete surgery
Phase of Trial: Phase III
Latest Information Update: 25 Jun 2018
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 15 Sep 2017 Status changed from active, no longer recruiting to completed.
- 14 Sep 2017 The trial has been completed in Germany.
- 16 Nov 2015 Interim results published in the Journal of Clinical Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History